Skip to main content

Drug Interactions between carvedilol and Scemblix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

carvedilol asciminib

Applies to: carvedilol and Scemblix (asciminib)

MONITOR: Coadministration with moderate inhibitors of CYP450 2C9 may increase the serum levels and effects of carvedilol. The mechanism is inhibition of CYP450 2C9, one of the primary isoenzymes involved in the metabolism of carvedilol. According to the prescribing information, CYP450 2C9 is thought to be of importance in the O-methylation pathway of S(-)-carvedilol. Further reductions in heart rate or cardiac conduction may occur.

MANAGEMENT: Patients should be monitored for signs of increased carvedilol effects, such as bradycardia or heart block.

References (2)
  1. (2001) "Product Information. Coreg (carvedilol)." SmithKline Beecham
  2. (2023) "Product Information. Coreg (carvedilol)." Waylis Therapuetics LLC

Drug and food interactions

Moderate

asciminib food

Applies to: Scemblix (asciminib)

ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of asciminib. When a single 40 mg dose of asciminib was administered with a low-fat meal (400 calories; 25% fat) in healthy volunteers, asciminib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 35% and 30%, respectively, compared to asciminib administered in the fasted state. Administration with a high-fat meal (1000 calories; 50% fat) decreased the Cmax and AUC of asciminib by 68% and 62%, respectively.

MANAGEMENT: To ensure adequate asciminib exposures, food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib.

References (2)
  1. (2021) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals
  2. (2022) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals UK Ltd, Scemblix 20 mg film-

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer